Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens.
What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of years of persistence by an extraordinary team of scientists, engineers, clinical advisors, and partners who refused to let go of a vision to transform human sight.
This is more than a milestone; it is a turning point for ophthalmology and for millions of people worldwide who are waiting for new solutions. And while we celebrate this historic success, we know our mission is far from complete. With more determination than ever, we move forward to deliver the Ocumetics Lens to patients everywhere and reshape the future of vision.
Best regards
Dean Burns
President, CEO and Director
Ocumetics Technology
Many of the questions we receive from investors relate to the process for obtaining US Food and Drug Administration (FDA) approval for surgical devices, such as the Ocumetics Accommodating Lens. This month’s message is focused on outlining how the process works and unpacking the steps required to obtain FDA approval. You will be thrilled to
Imagine a world in which glasses and traditional contact lenses become obsolete, and natural vision is restored with a simple and innovative solution.
That's precisely what we aim to achieve with the Ocumetics Accommodating Lens technology (“Ocumetics Accommodating Lens”).
